Khang & Khang LLP announces that it is investigating claims of potential
misrepresentations by Mallinckrodt Plc (“Mallinckrodt” or the “Company”)
(MNK).
The investigation focuses on whether the Company and its officers
violated securities laws by issuing misleading information to investors.
If you purchased shares of Mallinckrodt during the Class Period, please
contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman
Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by
e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
On November 9, 2015, Citron Research published a report that described
the Company’s abuse of the pharmaceutical reimbursement system. The
report claimed that Mallinckrodt has “significantly more downside” than
rival Valeant Pharmaceuticals International, Inc.
If you wish to learn more about this lawsuit, or if you have any
questions concerning this notice or your rights, please contact Joon M.
Khang, a prominent litigator for almost two decades, by telephone: (949)
419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20151123006406r1&sid=ntxv4&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20151123006406/en/
Copyright Business Wire 2015